股本结构
单位：万股
| 公告日期 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-12 | 2023-03-22 | 2022-11-09 |
|---|---|---|---|---|---|---|
| 证券总股本 | 154.07 | 154.07 | 153.26 | 151.67 | 1516.66 | 1516.66 |
| 普通股本 | 154.07 | 154.07 | 153.26 | 151.67 | 1516.66 | 1516.66 |
| 优先股 | 180.44 | 未披露 | 277.44 | 未披露 | 277.44 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-03 | 2023-06-30 | 2023-05-15 | 2022-12-31 | 2022-11-04 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-21 | 154.07 | 180.44 |
更多>>
From December 31, 2022 to December 31, 2023
Conversion of Series A preferred stock to shares of common stock
Issuance of common stock to adjust for reverse split rounding
|
2023-12-31 |
| 2023-11-09 | 154.07 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-08-10 | 153.26 | 277.44 |
更多>>
From April 1, 2023 to June 30, 2023
Issuance of common stock to adjust for reverse split rounding
|
2023-06-30 |
| 2023-05-12 | 151.67 | 未披露 |
更多>>
Xenetic Biosciences, Inc. announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.
|
2023-05-15 |
| 2023-03-22 | 1516.66 | 277.44 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of purchase warrants
Issuance of common stock in connection with purchase of in-process research and development
|
2022-12-31 |
| 2022-11-09 | 1516.66 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-08-11 | 1431.66 | 277.44 |
更多>>
From April 1, 2022 to June 30, 2022
Issuance of common stock in connection with purchase of in-process research and development
Exercise of purchase warrants
|
2022-06-30 |
| 2022-05-12 | 1431.66 | 未披露 | 定期报告 | 2022-05-06 |
| 2022-04-28 | 1344.16 | 未披露 | 定期报告 | 2022-04-21 |
| 2022-05-12 | 1344.13 | 277.44 |
更多>>
From January 1, 2022 to March 31,2022
Exercise of purchase warrants
|
2022-03-31 |
| 2022-03-22 | 1344.13 | 未披露 | 定期报告 | 2022-03-18 |
| 2022-03-22 | 1343.96 | 277.44 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants, net of issuance costs
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
Issuance of common stock in connection with warrant buyout
|
2021-12-31 |
| 2021-11-12 | 1338.80 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-12 | 1338.60 | 277.44 |
更多>>
From July 1, 2021 to September 30, 2021
Issuance of common stock and warrants, net of issuance costs
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
|
2021-09-30 |
| 2021-08-12 | 970.38 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-05-11 | 874.67 | 277.44 |
更多>>
From January 1, 2021 to March 31, 2021
Exercise of purchase warrants
|
2021-03-31 |
| 2021-03-16 | 874.67 | 未披露 | 定期报告 | 2021-03-11 |
| 2021-03-16 | 874.52 | 277.44 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock in December 2020 registered direct offering, net of issuance costs
Exercise of purchase warrants
Issuance of common stock to vendor
|
2020-12-31 |
| 2020-12-14 | 874.52 | 未披露 |
更多>>
1.Shares of common stock offered by the company pursuant to this prospectus supplement 2,448,980 shares of common stock.
2.The number of shares of common stock outstanding immediately after this offering is based on 6,296,227 shares of common stock outstanding as of December 9, 2020.
|
2020-12-14 |
| 2020-08-12 | 629.62 | 277.44 |
更多>>
From April 1, 2020 to June 30, 2020
Issuance of common stock to vendor
Exercise of purchase warrants
|
2020-06-30 |
| 2020-05-14 | 628.49 | 277.44 |
更多>>
From January 1, 2020 to March 06, 2020
Exercise of purchase warrants
|
2020-03-06 |
| 2020-03-26 | 606.54 | 277.44 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs
Issuance of common stock in connection with purchase of in-process research and development
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
Issuance of common stock to adjust for reverse split rounding
|
2019-12-31 |
| 2019-11-08 | 575.51 | 未披露 | 定期报告 | 2019-10-25 |
| 2019-11-14 | 563.35 | 277.44 |
更多>>
From June 30, 2019 to September 30, 2019
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs
Issuance of common stock in connection with purchase of in-process research and development
Exercise of pre-funded warrants
Exercise of purchase warrants
|
2019-09-30 |
| 2019-09-13 | 563.35 | 未披露 | 定期报告 | 2019-09-11 |
| 2019-08-14 | 374.39 | 未披露 | 定期报告 | 2019-08-09 |
| 2019-07-19 | 265.22 | 未披露 | 定期报告 | 2019-07-19 |
| 2019-08-14 | 92.22 | 277.44 |
更多>>
From January 1, 2019 to June 30, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
Exercise of pre-funded warrants
Issuance of common stock to vendor
Issuance of common stock to adjust for reverse split rounding
|
2019-06-30 |
| 2019-06-24 | 87.03 | 未披露 |
更多>>
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the opening of trading on June 25, 2019, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 503.
|
2019-06-25 |
| 2019-05-13 | 1044.39 | 277.44 |
更多>>
From January 1, 2019 to March 15, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
|
2019-03-15 |
| 2019-03-29 | 940.39 | 277.44 |
更多>>
from December 31, 2017 to June 30, 2018
Exercise of warrants
Conversion of Series B preferred stock to shares of common stock
|
2018-06-30 |
| 2018-03-30 | 871.75 | 309.07 |
更多>>
from December 31, 2016 to June 30, 2017
Conversion of Series B preferred stock to shares of common stock
Conversion of notes
|
2017-06-30 |
| 2017-05-15 | 871.75 | 未披露 | 定期报告 | 2017-05-11 |
| 2017-05-15 | 865.25 | 315.57 | 定期报告 | 2017-03-31 |
| 2017-05-02 | 865.25 | 未披露 | 定期报告 | 2017-02-10 |
| 2017-03-31 | 840.71 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Exchange of common stock for Series A preferred stock
Issuance of Series B preferred stock in public offering (net of issuance costs of $319,343)
Conversion of Series B preferred stock to shares of common stock
Conversion of notes
Settlement of accrued interest in common stock
Issuance of common stock in connection with completion of asset acquisition
Adjust shares in connection with 2014 reverse merger and 2016 reverse split
|
2016-12-31 |
| 2016-10-31 | 902.49 | 250.00 |
更多>>
2,500,000 shares of common stock issuable upon the conversion of Series B Preferred Stock sold in this offering;
970,000 shares of common stock issuable upon the conversion of Series A Preferred Stock;
On September 23, 2016, SynBio, one of our largest shareholders exchanged 970,000 shares of common stock in the Company for an equal number of shares of Series A Preferred Stock;
No issuance or exercise of stock options on or after June 30, 2016.
|
2016-11-07 |
| 2016-11-14 | 828.86 | 97.00 | 定期报告 | 2016-09-30 |
| 2016-10-11 | 902.49 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-06-24 | 460.61 | 未披露 |
更多>>
On June 1, 2016, the Company effected a reduction, on a 1 for 33 basis, in our authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding.
|
2016-06-02 |
| 2016-05-16 | 30841.37 | 未披露 | 定期报告 | 2016-05-16 |
| 2016-05-16 | 15199.41 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-30 | 15198.01 | 未披露 | 定期报告 | 2016-03-30 |
| 2016-03-30 | 15132.48 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock
Issuance of common stock in connection with pending asset acquisition
|
2015-12-31 |
From December 31, 2022 to December 31, 2023
Conversion of Series A preferred stock to shares of common stock
Issuance of common stock to adjust for reverse split rounding
From April 1, 2023 to June 30, 2023
Issuance of common stock to adjust for reverse split rounding
Xenetic Biosciences, Inc. announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock.
From December 31, 2021 to December 31, 2022
Exercise of purchase warrants
Issuance of common stock in connection with purchase of in-process research and development
From April 1, 2022 to June 30, 2022
Issuance of common stock in connection with purchase of in-process research and development
Exercise of purchase warrants
From January 1, 2022 to March 31,2022
Exercise of purchase warrants
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants, net of issuance costs
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
Issuance of common stock in connection with warrant buyout
From July 1, 2021 to September 30, 2021
Issuance of common stock and warrants, net of issuance costs
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
From January 1, 2021 to March 31, 2021
Exercise of purchase warrants
From December 31, 2019 to December 31, 2020
Issuance of common stock in December 2020 registered direct offering, net of issuance costs
Exercise of purchase warrants
Issuance of common stock to vendor
1.Shares of common stock offered by the company pursuant to this prospectus supplement 2,448,980 shares of common stock.
2.The number of shares of common stock outstanding immediately after this offering is based on 6,296,227 shares of common stock outstanding as of December 9, 2020.
From April 1, 2020 to June 30, 2020
Issuance of common stock to vendor
Exercise of purchase warrants
From January 1, 2020 to March 06, 2020
Exercise of purchase warrants
From December 31, 2018 to December 31, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs
Issuance of common stock in connection with purchase of in-process research and development
Exercise of pre-funded warrants
Exercise of purchase warrants
Issuance of common stock to vendor
Issuance of common stock to adjust for reverse split rounding
From June 30, 2019 to September 30, 2019
Issuance of common stock and warrants in July 2019 public offering, net of issuance costs
Issuance of common stock in connection with purchase of in-process research and development
Exercise of pre-funded warrants
Exercise of purchase warrants
From January 1, 2019 to June 30, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
Exercise of pre-funded warrants
Issuance of common stock to vendor
Issuance of common stock to adjust for reverse split rounding
Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the opening of trading on June 25, 2019, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 503.
From January 1, 2019 to March 15, 2019
Issuance of common stock and warrants in March 2019 registered direct offering, net of issuance costs
from December 31, 2017 to June 30, 2018
Exercise of warrants
Conversion of Series B preferred stock to shares of common stock
from December 31, 2016 to June 30, 2017
Conversion of Series B preferred stock to shares of common stock
Conversion of notes
from December 31, 2015 to December 31, 2016
Exchange of common stock for Series A preferred stock
Issuance of Series B preferred stock in public offering (net of issuance costs of $319,343)
Conversion of Series B preferred stock to shares of common stock
Conversion of notes
Settlement of accrued interest in common stock
Issuance of common stock in connection with completion of asset acquisition
Adjust shares in connection with 2014 reverse merger and 2016 reverse split
2,500,000 shares of common stock issuable upon the conversion of Series B Preferred Stock sold in this offering;
970,000 shares of common stock issuable upon the conversion of Series A Preferred Stock;
On September 23, 2016, SynBio, one of our largest shareholders exchanged 970,000 shares of common stock in the Company for an equal number of shares of Series A Preferred Stock;
No issuance or exercise of stock options on or after June 30, 2016.
On June 1, 2016, the Company effected a reduction, on a 1 for 33 basis, in our authorized common stock, par value $0.001, along with a corresponding and proportional decrease in the number of shares issued and outstanding.
From December 31, 2014 to December 31, 2015
Issuance of common stock
Issuance of common stock in connection with pending asset acquisition